Optimizing Cholesterol Treatment in Patients With Muscle Complaints.
Identifieur interne : 000519 ( PubMed/Corpus ); précédent : 000518; suivant : 000520Optimizing Cholesterol Treatment in Patients With Muscle Complaints.
Auteurs : Robert S. Rosenson ; Steven Baker ; Maciej Banach ; Kenneth M. Borow ; Lynne T. Braun ; Eric Bruckert ; Liam R. Brunham ; Alberico L. Catapano ; Marshall B. Elam ; G B John Mancini ; Patrick M. Moriarty ; Pamela B. Morris ; Paul Muntner ; Kausik K. Ray ; Erik S. Stroes ; Beth A. Taylor ; Valerie H. Taylor ; Gerald F. Watts ; Paul D. ThompsonSource :
- Journal of the American College of Cardiology [ 1558-3597 ] ; 2017.
English descriptors
- KwdEn :
- Anticholesteremic Agents (adverse effects), Anticholesteremic Agents (therapeutic use), Cardiovascular Diseases (blood), Cardiovascular Diseases (prevention & control), Cholesterol (blood), Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors (adverse effects), Hydroxymethylglutaryl-CoA Reductase Inhibitors (therapeutic use), Muscle, Skeletal (drug effects), Muscular Diseases (chemically induced), Risk Factors.
- MESH :
- chemical , adverse effects : Anticholesteremic Agents, Hydroxymethylglutaryl-CoA Reductase Inhibitors.
- chemical , blood : Cholesterol.
- chemical , therapeutic use : Anticholesteremic Agents, Hydroxymethylglutaryl-CoA Reductase Inhibitors.
- blood : Cardiovascular Diseases.
- chemically induced : Muscular Diseases.
- drug effects : Muscle, Skeletal.
- prevention & control : Cardiovascular Diseases.
- Humans, Risk Factors.
Abstract
Statins are highly effective for preventing cardiovascular events by reducing low-density lipoprotein cholesterol (LDL-C). However, many patients taking statins report muscle-related symptoms that prevent the use of guideline recommended doses. Patients with reported intolerance to statins have a high risk of cardiovascular events. Clinical strategies that optimize cardiovascular risk reduction through LDL-C lowering need to be applied in patients experiencing intolerable side effects that they attribute to statins. In this paper, the authors review definitions of statin intolerance, propose algorithms to better define statin intolerance, and describe approaches to optimize cardiovascular risk reduction among individuals reporting statin-associated muscle symptoms.
DOI: 10.1016/j.jacc.2017.07.752
PubMed: 28859793
Links to Exploration step
pubmed:28859793Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Optimizing Cholesterol Treatment in Patients With Muscle Complaints.</title><author><name sortKey="Rosenson, Robert S" sort="Rosenson, Robert S" uniqKey="Rosenson R" first="Robert S" last="Rosenson">Robert S. Rosenson</name><affiliation><nlm:affiliation>Department of Medicine, Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: robert.rosenson@mssm.edu.</nlm:affiliation></affiliation></author><author><name sortKey="Baker, Steven" sort="Baker, Steven" uniqKey="Baker S" first="Steven" last="Baker">Steven Baker</name><affiliation><nlm:affiliation>Department of Medicine, Neuromuscular Disease Clinic, McMaster University, Hamilton, Ontario, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Banach, Maciej" sort="Banach, Maciej" uniqKey="Banach M" first="Maciej" last="Banach">Maciej Banach</name><affiliation><nlm:affiliation>Department of Hypertension, Medical University of Lodz, Lodz, Poland; Cardiovascular Research Centre, University of Zielona Gora, Zielona Gora, Poland.</nlm:affiliation></affiliation></author><author><name sortKey="Borow, Kenneth M" sort="Borow, Kenneth M" uniqKey="Borow K" first="Kenneth M" last="Borow">Kenneth M. Borow</name><affiliation><nlm:affiliation>National Medication Safety, Outcomes and Adherence Program, MediMergent, Rockville, Maryland.</nlm:affiliation></affiliation></author><author><name sortKey="Braun, Lynne T" sort="Braun, Lynne T" uniqKey="Braun L" first="Lynne T" last="Braun">Lynne T. Braun</name><affiliation><nlm:affiliation>Department of Adult Health and Gerentologic Nursing, College of Nursing, Rush University Medical Center, Chicago, Illinois.</nlm:affiliation></affiliation></author><author><name sortKey="Bruckert, Eric" sort="Bruckert, Eric" uniqKey="Bruckert E" first="Eric" last="Bruckert">Eric Bruckert</name><affiliation><nlm:affiliation>Institute of Cardiometabolism and Nutrition (ICAN), Endocrinology Department, Hopital Pitié Salpetrière, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Brunham, Liam R" sort="Brunham, Liam R" uniqKey="Brunham L" first="Liam R" last="Brunham">Liam R. Brunham</name><affiliation><nlm:affiliation>Department of Medicine, University of Vancouver, British Columbia, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Catapano, Alberico L" sort="Catapano, Alberico L" uniqKey="Catapano A" first="Alberico L" last="Catapano">Alberico L. Catapano</name><affiliation><nlm:affiliation>Department of Pharmacological and Biomolecular Sciences, University of Milan, IRCCS Multimedica, Milan, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Elam, Marshall B" sort="Elam, Marshall B" uniqKey="Elam M" first="Marshall B" last="Elam">Marshall B. Elam</name><affiliation><nlm:affiliation>Departments of Pharmacology and Medicine, University of Tennessee Health Sciences Center, Memphis, Tennessee.</nlm:affiliation></affiliation></author><author><name sortKey="Mancini, G B John" sort="Mancini, G B John" uniqKey="Mancini G" first="G B John" last="Mancini">G B John Mancini</name><affiliation><nlm:affiliation>Department of Medicine, Division of Cardiology, University of British Columbia, Vancouver, British Columbia, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Moriarty, Patrick M" sort="Moriarty, Patrick M" uniqKey="Moriarty P" first="Patrick M" last="Moriarty">Patrick M. Moriarty</name><affiliation><nlm:affiliation>Division of Clinical Pharmacology, Division of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas.</nlm:affiliation></affiliation></author><author><name sortKey="Morris, Pamela B" sort="Morris, Pamela B" uniqKey="Morris P" first="Pamela B" last="Morris">Pamela B. Morris</name><affiliation><nlm:affiliation>Department of Medicine, Division of Cardiology, Medical University of South Carolina, Charleston, South Carolina.</nlm:affiliation></affiliation></author><author><name sortKey="Muntner, Paul" sort="Muntner, Paul" uniqKey="Muntner P" first="Paul" last="Muntner">Paul Muntner</name><affiliation><nlm:affiliation>Department of Epidemiology, University of Alabama Birmingham, Birmingham, Alabama.</nlm:affiliation></affiliation></author><author><name sortKey="Ray, Kausik K" sort="Ray, Kausik K" uniqKey="Ray K" first="Kausik K" last="Ray">Kausik K. Ray</name><affiliation><nlm:affiliation>Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College London, London, United Kingdom.</nlm:affiliation></affiliation></author><author><name sortKey="Stroes, Erik S" sort="Stroes, Erik S" uniqKey="Stroes E" first="Erik S" last="Stroes">Erik S. Stroes</name><affiliation><nlm:affiliation>Department of Vascular Medicine, AMC, Amsterdam, the Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Taylor, Beth A" sort="Taylor, Beth A" uniqKey="Taylor B" first="Beth A" last="Taylor">Beth A. Taylor</name><affiliation><nlm:affiliation>Department of Kinesiology, University of Connecticut, Storrs, Connecticut; Division of Cardiology, Hartford Hospital, Hartford, Connecticut.</nlm:affiliation></affiliation></author><author><name sortKey="Taylor, Valerie H" sort="Taylor, Valerie H" uniqKey="Taylor V" first="Valerie H" last="Taylor">Valerie H. Taylor</name><affiliation><nlm:affiliation>Department of Psychiatry, University of Toronto, Women's College Hospital, Toronto, Ontario, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Watts, Gerald F" sort="Watts, Gerald F" uniqKey="Watts G" first="Gerald F" last="Watts">Gerald F. Watts</name><affiliation><nlm:affiliation>Cardiometabolic Service, Department of Cardiology, Royal Perth Hospital; School of Medicine, University of Western Australia, Perth, Western Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Thompson, Paul D" sort="Thompson, Paul D" uniqKey="Thompson P" first="Paul D" last="Thompson">Paul D. Thompson</name><affiliation><nlm:affiliation>Division of Cardiology, Hartford Hospital, Hartford, Connecticut.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28859793</idno><idno type="pmid">28859793</idno><idno type="doi">10.1016/j.jacc.2017.07.752</idno><idno type="wicri:Area/PubMed/Corpus">000519</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000519</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Optimizing Cholesterol Treatment in Patients With Muscle Complaints.</title><author><name sortKey="Rosenson, Robert S" sort="Rosenson, Robert S" uniqKey="Rosenson R" first="Robert S" last="Rosenson">Robert S. Rosenson</name><affiliation><nlm:affiliation>Department of Medicine, Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: robert.rosenson@mssm.edu.</nlm:affiliation></affiliation></author><author><name sortKey="Baker, Steven" sort="Baker, Steven" uniqKey="Baker S" first="Steven" last="Baker">Steven Baker</name><affiliation><nlm:affiliation>Department of Medicine, Neuromuscular Disease Clinic, McMaster University, Hamilton, Ontario, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Banach, Maciej" sort="Banach, Maciej" uniqKey="Banach M" first="Maciej" last="Banach">Maciej Banach</name><affiliation><nlm:affiliation>Department of Hypertension, Medical University of Lodz, Lodz, Poland; Cardiovascular Research Centre, University of Zielona Gora, Zielona Gora, Poland.</nlm:affiliation></affiliation></author><author><name sortKey="Borow, Kenneth M" sort="Borow, Kenneth M" uniqKey="Borow K" first="Kenneth M" last="Borow">Kenneth M. Borow</name><affiliation><nlm:affiliation>National Medication Safety, Outcomes and Adherence Program, MediMergent, Rockville, Maryland.</nlm:affiliation></affiliation></author><author><name sortKey="Braun, Lynne T" sort="Braun, Lynne T" uniqKey="Braun L" first="Lynne T" last="Braun">Lynne T. Braun</name><affiliation><nlm:affiliation>Department of Adult Health and Gerentologic Nursing, College of Nursing, Rush University Medical Center, Chicago, Illinois.</nlm:affiliation></affiliation></author><author><name sortKey="Bruckert, Eric" sort="Bruckert, Eric" uniqKey="Bruckert E" first="Eric" last="Bruckert">Eric Bruckert</name><affiliation><nlm:affiliation>Institute of Cardiometabolism and Nutrition (ICAN), Endocrinology Department, Hopital Pitié Salpetrière, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Brunham, Liam R" sort="Brunham, Liam R" uniqKey="Brunham L" first="Liam R" last="Brunham">Liam R. Brunham</name><affiliation><nlm:affiliation>Department of Medicine, University of Vancouver, British Columbia, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Catapano, Alberico L" sort="Catapano, Alberico L" uniqKey="Catapano A" first="Alberico L" last="Catapano">Alberico L. Catapano</name><affiliation><nlm:affiliation>Department of Pharmacological and Biomolecular Sciences, University of Milan, IRCCS Multimedica, Milan, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Elam, Marshall B" sort="Elam, Marshall B" uniqKey="Elam M" first="Marshall B" last="Elam">Marshall B. Elam</name><affiliation><nlm:affiliation>Departments of Pharmacology and Medicine, University of Tennessee Health Sciences Center, Memphis, Tennessee.</nlm:affiliation></affiliation></author><author><name sortKey="Mancini, G B John" sort="Mancini, G B John" uniqKey="Mancini G" first="G B John" last="Mancini">G B John Mancini</name><affiliation><nlm:affiliation>Department of Medicine, Division of Cardiology, University of British Columbia, Vancouver, British Columbia, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Moriarty, Patrick M" sort="Moriarty, Patrick M" uniqKey="Moriarty P" first="Patrick M" last="Moriarty">Patrick M. Moriarty</name><affiliation><nlm:affiliation>Division of Clinical Pharmacology, Division of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas.</nlm:affiliation></affiliation></author><author><name sortKey="Morris, Pamela B" sort="Morris, Pamela B" uniqKey="Morris P" first="Pamela B" last="Morris">Pamela B. Morris</name><affiliation><nlm:affiliation>Department of Medicine, Division of Cardiology, Medical University of South Carolina, Charleston, South Carolina.</nlm:affiliation></affiliation></author><author><name sortKey="Muntner, Paul" sort="Muntner, Paul" uniqKey="Muntner P" first="Paul" last="Muntner">Paul Muntner</name><affiliation><nlm:affiliation>Department of Epidemiology, University of Alabama Birmingham, Birmingham, Alabama.</nlm:affiliation></affiliation></author><author><name sortKey="Ray, Kausik K" sort="Ray, Kausik K" uniqKey="Ray K" first="Kausik K" last="Ray">Kausik K. Ray</name><affiliation><nlm:affiliation>Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College London, London, United Kingdom.</nlm:affiliation></affiliation></author><author><name sortKey="Stroes, Erik S" sort="Stroes, Erik S" uniqKey="Stroes E" first="Erik S" last="Stroes">Erik S. Stroes</name><affiliation><nlm:affiliation>Department of Vascular Medicine, AMC, Amsterdam, the Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Taylor, Beth A" sort="Taylor, Beth A" uniqKey="Taylor B" first="Beth A" last="Taylor">Beth A. Taylor</name><affiliation><nlm:affiliation>Department of Kinesiology, University of Connecticut, Storrs, Connecticut; Division of Cardiology, Hartford Hospital, Hartford, Connecticut.</nlm:affiliation></affiliation></author><author><name sortKey="Taylor, Valerie H" sort="Taylor, Valerie H" uniqKey="Taylor V" first="Valerie H" last="Taylor">Valerie H. Taylor</name><affiliation><nlm:affiliation>Department of Psychiatry, University of Toronto, Women's College Hospital, Toronto, Ontario, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Watts, Gerald F" sort="Watts, Gerald F" uniqKey="Watts G" first="Gerald F" last="Watts">Gerald F. Watts</name><affiliation><nlm:affiliation>Cardiometabolic Service, Department of Cardiology, Royal Perth Hospital; School of Medicine, University of Western Australia, Perth, Western Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Thompson, Paul D" sort="Thompson, Paul D" uniqKey="Thompson P" first="Paul D" last="Thompson">Paul D. Thompson</name><affiliation><nlm:affiliation>Division of Cardiology, Hartford Hospital, Hartford, Connecticut.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Journal of the American College of Cardiology</title><idno type="eISSN">1558-3597</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anticholesteremic Agents (adverse effects)</term><term>Anticholesteremic Agents (therapeutic use)</term><term>Cardiovascular Diseases (blood)</term><term>Cardiovascular Diseases (prevention & control)</term><term>Cholesterol (blood)</term><term>Humans</term><term>Hydroxymethylglutaryl-CoA Reductase Inhibitors (adverse effects)</term><term>Hydroxymethylglutaryl-CoA Reductase Inhibitors (therapeutic use)</term><term>Muscle, Skeletal (drug effects)</term><term>Muscular Diseases (chemically induced)</term><term>Risk Factors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Anticholesteremic Agents</term><term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Cholesterol</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anticholesteremic Agents</term><term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Cardiovascular Diseases</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Muscular Diseases</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Muscle, Skeletal</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Cardiovascular Diseases</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Risk Factors</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Statins are highly effective for preventing cardiovascular events by reducing low-density lipoprotein cholesterol (LDL-C). However, many patients taking statins report muscle-related symptoms that prevent the use of guideline recommended doses. Patients with reported intolerance to statins have a high risk of cardiovascular events. Clinical strategies that optimize cardiovascular risk reduction through LDL-C lowering need to be applied in patients experiencing intolerable side effects that they attribute to statins. In this paper, the authors review definitions of statin intolerance, propose algorithms to better define statin intolerance, and describe approaches to optimize cardiovascular risk reduction among individuals reporting statin-associated muscle symptoms.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28859793</PMID><DateCreated><Year>2017</Year><Month>09</Month><Day>01</Day></DateCreated><DateCompleted><Year>2017</Year><Month>09</Month><Day>13</Day></DateCompleted><DateRevised><Year>2017</Year><Month>09</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1558-3597</ISSN><JournalIssue CitedMedium="Internet"><Volume>70</Volume><Issue>10</Issue><PubDate><Year>2017</Year><Month>Sep</Month><Day>05</Day></PubDate></JournalIssue><Title>Journal of the American College of Cardiology</Title><ISOAbbreviation>J. Am. Coll. Cardiol.</ISOAbbreviation></Journal><ArticleTitle>Optimizing Cholesterol Treatment in Patients With Muscle Complaints.</ArticleTitle><Pagination><MedlinePgn>1290-1301</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0735-1097(17)38966-0</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jacc.2017.07.752</ELocationID><Abstract><AbstractText>Statins are highly effective for preventing cardiovascular events by reducing low-density lipoprotein cholesterol (LDL-C). However, many patients taking statins report muscle-related symptoms that prevent the use of guideline recommended doses. Patients with reported intolerance to statins have a high risk of cardiovascular events. Clinical strategies that optimize cardiovascular risk reduction through LDL-C lowering need to be applied in patients experiencing intolerable side effects that they attribute to statins. In this paper, the authors review definitions of statin intolerance, propose algorithms to better define statin intolerance, and describe approaches to optimize cardiovascular risk reduction among individuals reporting statin-associated muscle symptoms.</AbstractText><CopyrightInformation>Copyright © 2017 American College of Cardiology Foundation. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rosenson</LastName><ForeName>Robert S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Department of Medicine, Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: robert.rosenson@mssm.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baker</LastName><ForeName>Steven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine, Neuromuscular Disease Clinic, McMaster University, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Banach</LastName><ForeName>Maciej</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Hypertension, Medical University of Lodz, Lodz, Poland; Cardiovascular Research Centre, University of Zielona Gora, Zielona Gora, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borow</LastName><ForeName>Kenneth M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>National Medication Safety, Outcomes and Adherence Program, MediMergent, Rockville, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Braun</LastName><ForeName>Lynne T</ForeName><Initials>LT</Initials><AffiliationInfo><Affiliation>Department of Adult Health and Gerentologic Nursing, College of Nursing, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bruckert</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Institute of Cardiometabolism and Nutrition (ICAN), Endocrinology Department, Hopital Pitié Salpetrière, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brunham</LastName><ForeName>Liam R</ForeName><Initials>LR</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Catapano</LastName><ForeName>Alberico L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Department of Pharmacological and Biomolecular Sciences, University of Milan, IRCCS Multimedica, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elam</LastName><ForeName>Marshall B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Departments of Pharmacology and Medicine, University of Tennessee Health Sciences Center, Memphis, Tennessee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mancini</LastName><ForeName>G B John</ForeName><Initials>GBJ</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Cardiology, University of British Columbia, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moriarty</LastName><ForeName>Patrick M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Division of Clinical Pharmacology, Division of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>Pamela B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Cardiology, Medical University of South Carolina, Charleston, South Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muntner</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, University of Alabama Birmingham, Birmingham, Alabama.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ray</LastName><ForeName>Kausik K</ForeName><Initials>KK</Initials><AffiliationInfo><Affiliation>Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stroes</LastName><ForeName>Erik S</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>Department of Vascular Medicine, AMC, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>Beth A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Department of Kinesiology, University of Connecticut, Storrs, Connecticut; Division of Cardiology, Hartford Hospital, Hartford, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>Valerie H</ForeName><Initials>VH</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Toronto, Women's College Hospital, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watts</LastName><ForeName>Gerald F</ForeName><Initials>GF</Initials><AffiliationInfo><Affiliation>Cardiometabolic Service, Department of Cardiology, Royal Perth Hospital; School of Medicine, University of Western Australia, Perth, Western Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Paul D</ForeName><Initials>PD</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Hartford Hospital, Hartford, Connecticut.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Coll Cardiol</MedlineTA><NlmUniqueID>8301365</NlmUniqueID><ISSNLinking>0735-1097</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000924">Anticholesteremic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>97C5T2UQ7J</RegistryNumber><NameOfSubstance UI="D002784">Cholesterol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000924" MajorTopicYN="N">Anticholesteremic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002784" MajorTopicYN="N">Cholesterol</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019161" MajorTopicYN="N">Hydroxymethylglutaryl-CoA Reductase Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018482" MajorTopicYN="N">Muscle, Skeletal</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009135" MajorTopicYN="N">Muscular Diseases</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cardiovascular disease</Keyword><Keyword MajorTopicYN="N">low-density lipoprotein</Keyword><Keyword MajorTopicYN="N">myalgia</Keyword><Keyword MajorTopicYN="N">myopathy</Keyword><Keyword MajorTopicYN="N">statin intolerance</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>05</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>07</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>07</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>9</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>9</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>9</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28859793</ArticleId><ArticleId IdType="pii">S0735-1097(17)38966-0</ArticleId><ArticleId IdType="doi">10.1016/j.jacc.2017.07.752</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000519 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000519 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:28859793
|texte= Optimizing Cholesterol Treatment in Patients With Muscle Complaints.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:28859793" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |